Stock MDP MEDEXUS PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Market Closed - Toronto S.E.
Other stock markets
 03:57:29 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.79 CAD +1.13% Intraday chart for Medexus Pharmaceuticals Inc. -6.77% -27.53%
Mar. 26 Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R) CI
Feb. 09 Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85 MT

Evolution of the average Target Price on Medexus Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

ab04fdacf62783.zb9GtKtl7h7Lkfr6TDywekN2QrcYdPSXCpdowr8MLTM.oIpwhsIqq1mc9NeLCwvSPXpGOuA1WZnwJ6Ixuu9cFGyO9iXswVaHcJrVkQ~0b757e8a528ef684ade9ac2d58c13c12

Analyst Recommendations on Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85 MT
Medexus Pharmaceuticals Buy Rating Maintained by Stifel GMP as Drug Approvals Awaited; Price Target Lowered to C$11.00 MT
Medexus Pharmaceuticals Initiated at Outperform With $5.50 Target at Raymond James MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.79 CAD
Average target price
3.208 CAD
Spread / Average Target
+79.24%
High Price Target
5.9 CAD
Spread / Highest target
+229.61%
Low Price Target
2 CAD
Spread / Lowest Target
+11.73%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Medexus Pharmaceuticals Inc.

Stifel GMP
Raymond James

Ratings for Medexus Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MDP Stock
  4. Consensus Medexus Pharmaceuticals Inc.